NovaBay's NeutroPhase(R) Used In New Therapeutic Technique For Management Of Necrotizing Fasciitis

Case Study Presented at the 2012 Fall Symposium on Advanced Wound Care

EMERYVILLE, Calif., Sept. 13, 2012 (GLOBE NEWSWIRE) -- NovaBay ® Pharmaceuticals, Inc. (NYSE-MKT:NBY), a clinical-stage biotechnology company developing its first-in-class, anti-infective Aganocide ® compounds for the local non-systemic treatment and prevention of infections, today announced NeutroPhase Skin and Wound Cleanser in combination with negative pressure wound therapy (NPWT) is featured in a case study as a new therapeutic technique for the management of necrotizing fasciitis. The case study titled, "Treatment of Acute Necrotizing Fasciitis Using Adjunctive Pure Hypochlorous Acid," was presented at the 2012 Fall Symposium on Advanced Wound Care (SAWC), in Baltimore, Md.

Necrotizing fasciitis, also known as flesh eating bacteria, is most commonly caused by the group A streptococcus bacteria. The bacteria itself can be cleared with an aggressive course of intravenous antibiotic therapy; however, the toxins secreted by the bacteria are known to destroy soft tissue at the subcutaneous level, causing toxic shock and in some cases death. Because of this, current standard of care for necrotizing fasciitis also involves an aggressive surgical debridement of necrotic tissue, which often leads to multiple amputations.

"The successful outcome of this particular patient case is exciting because it has lead us to the possible discovery of a new treatment protocol that could preempt the practice of debridement for the treatment of flesh eating bacterial infection," stated, John Crew, MD, FACS, Medical Director, San Francisco Center for Advanced Wound Care at Seton Medical Center, San Francisco, Calif., and co-author of the study. "The new therapeutic technique combines aggressive wound irrigation with a unique pure hypochlorous acid solution known as NeutroPhase and negative pressure wound therapy, which lead to the full recovery of this patient. It is well known that hypochlorous acid has potent in-vitro activity against Strep A bacteria and more importantly has been shown in laboratory studies that it has the ability to neutralize toxins and superantigens produced by the group A streptococcus."

If you liked this article you might like

3 Biotech Stocks Under $10 to Trade for Big Breakouts

Novabay Pharmaceuticals (NBY) Stock Spikes After FDA Approves Disinfection System

Insider Trading Alert - NBY, WPX And KTOS Traded By Insiders

Insider Trading Alert - EVTC, CRM And NBY Traded By Insiders

Insider Trading Alert - CGIX, NBY And BIOA Traded By Insiders